Two novel agents targeting angiopoietin-like protein 3 demonstrated safety and lipid-lowering capabilities in phase 2 trials, ...

Obesity and related metabolic disorders, such as hyperlipidemia and non-alcoholic fatty liver disease, have become ...

Obesity and related metabolic disorders, such as hyperlipidemia and non-alcoholic fatty liver disease, have become ...

MetaVia Inc. , a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract highlighting data from its Phase 2a clinical trial of DA-1241, ...

BPGbio, Inc., a leading biology-first, AI-powered clinical-stage biopharma company focused on mitochondrial biology and protein homeostasis, today announced the presentation of seven presentations at ...

Non-alcoholic fatty liver disease (NAFLD) is a hepatic metabolic syndrome resulting from lipid metabolic imbalance.

Duodenal mucosal resurfacing (DMR), a new-style endoscopic procedure using hydrothermal energy to ablate this thickened layer ...

Age-related macular degeneration (AMD), the leading cause of adult blindness, affects nearly half of Oklahomans over age 80.

Non-alcoholic fatty liver disease (NAFLD) is a hepatic metabolic syndrome resulting from lipid metabolic imbalance.

Researchers have identified that an enzyme involved in lipid metabolism speeds up the immune system changes associated with ...

The study highlights a promising new approach to fight glioblastoma giving hope for future advancements in cancer treatment ...

Lipid metabolism has emerged as a central player in the progression and therapy resistance of breast cancer, particularly the aggressive subtype known as triple-negative breast cancer (TNBC).